Show simple item record

First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors

dc.contributor.authorDulloo, S.
dc.contributor.authorFennell, D. A.
dc.contributor.authorSzlosarek, P. W.
dc.contributor.authorThistlethwaite, Fiona C
dc.contributor.authorLord, S.
dc.contributor.authorRahman, N. M.
dc.contributor.authorGreystoke, A.
dc.contributor.authorCunniff, B.
dc.contributor.authorDzialo, J.
dc.contributor.authorPoile, C.
dc.contributor.authorPanchal, R.
dc.contributor.authorDuncan, J.
dc.contributor.authorGraham, P.
dc.contributor.authorBexon, A. S.
dc.contributor.authorNaumov, G.
dc.contributor.authorSpicer, J.
dc.date.accessioned2023-01-24T10:32:26Z
dc.date.available2023-01-24T10:32:26Z
dc.date.issued2022en
dc.identifier.citationDulloo S, Fennell DA, Szlosarek PW, Thistlethwaite F, Lord S, Rahman NM, et al. First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors. Annals of Oncology. 2022 Sep;33(7):S1292-S3. PubMed PMID: WOS:000866211602195.en
dc.identifier.doi10.1016/j.annonc.2022.07.1722en
dc.identifier.urihttp://hdl.handle.net/10541/625979
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.07.1722en
dc.titleFirst-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumorsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentOncology Department, Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicesteren
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record